{"id":"gsk1358820","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Headache"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"IL-13 is a critical mediator of type 2 inflammation implicated in conditions such as asthma and atopic dermatitis. By neutralizing IL-13, GSK1358820 reduces downstream inflammatory signaling and tissue remodeling associated with type 2 immune responses. This mechanism aims to reduce airway inflammation, mucus production, and other pathological features of allergic and eosinophilic diseases.","oneSentence":"GSK1358820 is a monoclonal antibody that targets and inhibits IL-13, a key cytokine involved in type 2 inflammatory responses.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T00:47:32.864Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Asthma (type 2 inflammation)"},{"name":"Atopic dermatitis"}]},"trialDetails":[{"nctId":"NCT02849418","phase":"PHASE3","title":"Efficacy and Safety Study of GSK1358820 in Japanese Patients With Urinary Incontinence Due to Neurogenic Detrusor Overactivity","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-10-11","conditions":"Urinary Bladder, Overactive","enrollment":21},{"nctId":"NCT02820844","phase":"PHASE3","title":"Efficacy and Safety of GSK1358820 in Subjects With Overactive Bladder","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2016-08-10","conditions":"Urinary Bladder, Overactive","enrollment":250},{"nctId":"NCT03261167","phase":"PHASE3","title":"A Phase III Study to Evaluate the Efficacy and Safety of GSK1358820 in Subjects With Post-stroke Upper Limb Spasticity","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-08-02","conditions":"Spasticity, Post-Stroke","enrollment":124},{"nctId":"NCT01153815","phase":"PHASE3","title":"A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Upper Limb Spasticity","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04","conditions":"Cerebrovascular Accident","enrollment":170},{"nctId":"NCT00460564","phase":"PHASE3","title":"Study Of GSK1358820 In Patients With Post-Stroke Upper Limb Spasticity","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Post-Stroke Spasticity, Cerebrovascular Accident","enrollment":109},{"nctId":"NCT01205451","phase":"PHASE3","title":"A Multicenter, Open-label, Single Dose Study of the Safety and Efficacy of GSK1358820 (Botulinum Toxin Type A) in Chinese Subjects With Post-stroke Focal Upper Limb Spasticity","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-09","conditions":"Spasticity, Post-Stroke","enrollment":109},{"nctId":"NCT01584843","phase":"PHASE3","title":"Efficacy and Safety of GSK1358820 (Botulinum Toxin Type A) in Patients With Strabismus","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2012-05","conditions":"Strabismus","enrollment":41},{"nctId":"NCT01128738","phase":"PHASE3","title":"GSK1358820 (Botulinum Toxin A) PhIII DB & OL Study in Patients With Axillary Hyperhidrosis","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2010-04","conditions":"Hyperhidrosis","enrollment":152},{"nctId":"NCT00460655","phase":"PHASE3","title":"Study of GSK1358820 In Patients With Post-Stroke Lower Limb Spasticity","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2007-05","conditions":"Post-Stroke Spasticity, Cerebrovascular Accident","enrollment":120}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Botulinum Toxin Type A"],"phase":"phase_3","status":"active","brandName":"GSK1358820","genericName":"GSK1358820","companyName":"GlaxoSmithKline","companyId":"gsk","modality":"Small molecule","firstApprovalDate":"","aiSummary":"GSK1358820 is a monoclonal antibody that targets and inhibits IL-13, a key cytokine involved in type 2 inflammatory responses. Used for Asthma (type 2 inflammation), Atopic dermatitis.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}